From Chromadex’s (NR seller) earnings call last week:

CEO Rob Fried:

“Since our last update, 4 additional human trials on Nicotinamide Riboside (NR) have been registered, one of which I want to highlight that aims to explore how NR effects the energy and immune related features of specific immune cells, myeloid cells in different populations.

Inflammation or the concept of “inflamaging” remains an important area of research on how NR can play an active and beneficial role in reducing inflammation as a healthy aging benefit.

In August, the results of a clinical study published in the peer reviewed journal Cell Reports indicated that NR was successful in reducing inflammation in both healthy subjects and in cells derived from psoriasis patients.

This marks a significant achievement in NAD research, as it further validates NR as the proactive safeguard against inflammatory cytokines, and healthy individuals and in those with inflammation related disorders.

…In addition, the results of a clinical study that investigated the safety benefits of long term NR supplementation in individuals with Ataxia, a rare genetic neurodegenerative disorder, were published in October.

Previous studies have shown that NAD deficiency plays a role in disease mechanisms underlying DNA repair disorders, such as AT.

The results of this clinical study build on those from a previously published short term trial and confirm that long term supplementation of NR was safe, and well tolerated, and improved motor coordination and eye movements in patients with AT of various ages.

Related:

  • Anecdote #17: Psoriasis (Link)
  • NR and Inflammation (Link)
  • Nicotinamide Riboside “NR” (FAQs) (Reviews)

Twitter @RaisingNAD